Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp enal dysfunction is a frequent comorbidity among patients with chronic heart failure and is closely associated with a worse outcome. Beta-blockade is currently a popular approach to treating a broad spectrum of systolic heart failure, but β-blockers are clinically underutilized in patients with heart failure and concomitant renal dysfunction, 1 and prescription rates for β-blockers are inversely related to renal function. 2 One reason for this underutilization is a lack of information about the influence of renal dysfunction on the effects of β-blockade therapy for heart failure. The short-term administration of β-blockers often reduces cardiac output and renal blood flow, which can worsen renal function, and many large clinical studies on the long-term effects of β-blockers have excluded patients with advanced renal dysfunction and serum creatinine values >2.0−2.8 mg/dl. Fear of adverse potential and limited information about long-term effects and tolerability might explain the clinical hesitation to administer β-blockers for heart failure and concomitant chronic kidney disease.
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Several recent retrospective and prospective studies, as well as sub-analyses of 2 large randomized clinical trials, have provided valuable information regarding this issue. Ito et al found that β-blockers improve cardiac function in patients with heart failure and baseline estimated glomerular filtration rates (eGFR) of below and above 65.9 ml · min -1 · 1.73 m −2 body surface area. 3 They also demonstrated that β-blockers preserve renal function for over 16 weeks in patients with lower baseline eGFR. Two prospective cohort studies evaluated the impact of renal dysfunction on the benefits of β-blockers for heart failure 1,2 and both found a similar reduction in 1-year mortality rates among patients with eGFR <60 vs ≥60 ml · min -1 · 1.73 m −2 . However, these studies included many patients with mildly reduced renal function among the groups with a lower eGFR. Consequently, the effects of β-blockers for patients with more severe renal dysfunction were inconclusive in these studies.
The Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF) had no exclusion criteria associated with baseline serum creatinine values. A post hoc analysis of MERIT-HF separated 3,965 patients into 3 renal function subgroups based on eGFR >60, 45-60 and <45 ml · min -1 · 1.73 m −2 . 4 The results showed that eGFR was a powerful predictor of death and of hospitalization because of worsening heart failure. Metoprolol CR/XL was equally effective in reducing the mortality rates of patients with eGFR <45 and >60 ml · min -1 · 1.73 m −2 (Table) . Notably, metoprolol CR/XL showed a higher reduction in the risk 
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of hospitalization because of heart failure or the combined endpoint of all-cause mortality/heart failure in patients with eGFR <45 than in those with >60 ml · min -1 · 1.73 m −2 . The second Cardiac Insufficiency Bisoprolol Study (CIBIS-II) had less stringent renal exclusion criteria than many other trials, as it accepted patients with a serum creatinine value of up to 3.4 mg/dl. Thus, renal dysfunction was moderate to severe in approximately one-third of this study population. A post hoc analysis of CIBIS-II that divided 2,622 patients into subgroups according to baseline eGFR values of <45, 45-60, 60-75 and ≥75 ml · min -1 · 1.73 m −2 associated a lower baseline eGFR with higher mortality. 5 After multivariate adjustment, the effect of bisoprolol on the relative risk for hospitalization because of all-cause mortality and heart failure was not influenced by baseline renal function (Table) . The rate of bisoprolol discontinuation was higher in patients with eGFR <45 ml · min -1 · 1.73 m −2 . Nevertheless, the absolute benefit of bisoprolol was greater for patients with than without chronic kidney disease. These results indicate that β-blockers should certainly be administered even to patients with moderate to severe renal dysfunction. The same or better outcomes of β-blockers for patients with heart failure and concomitant renal dysfunction might be pathophysiologically associated with overactivation of the sympathetic nervous system by these coexistent pathologies. The findings of Ito et al might reflect this association. Baseline plasma norepinephrine concentrations were higher in patients with lower than with higher baseline eGFR. Plasma norepinephrine concentrations and eGFR significantly interacted in terms of β-blockers.
The question then arises as to the optimal β-blocker that should be administered to patients with heart failure and concomitant renal dysfunction. Some β-blockers, such as atenolol, that are primarily excreted by the renal route should be avoided. Bisoprolol is a selective β-1 antagonist that is excreted via both the renal and hepatic routes. Metoprolol is also a β-1 selective blocker, but it is predominantly excreted via the hepatic route. The sub-analyses of both MERIT-HF 4 and CIBIS-II 5 found that the discontinuation rate because of adverse events increased with a decrease in renal function. However, the discontinuation rates among patients with eGFR <45 ml · min -1 · 1.73 m −2 in MERIT-HF was lower for metoprolol CR/XL than for a placebo, but significantly higher in CIBIS-II for bisoprolol than for a placebo (hazard ratio 1.54, 95% confidence interval 1.01-2.33). The excretion routes of the 2 drugs could explain this difference. Bisoprolol should be cautiously administered and the dosage should be adjusted for patients with reduced renal function. Carvedilol is a nonselective β-adrenergic antagonist with α1-blocking activity that is predominantly eliminated through hepatic metabolism. Non-selective β-blockers without intrinsic sympathomimetic activities have the potential to reduce renal blood flow and to cause a decrease in GFR. In contrast, α1-adrenergic blockers reduce renovascular resistance and preserve renal blood flow and GFR. Furthermore, carvedilol has an antioxidant effect that might contribute to protection against glomerular damage. A few studies have investigated the effect of carvedilol on renal function in patients with heart failure and preserved renal function. Carvedilol significantly increased renal blood flow, whereas metoprolol CR/XL did not, in dogs with pacing-induced heart failure. 6 A randomized comparison between carvedilol and metoprolol among 14 patients with heart failure and normal renal function found that only carvedilol increased renal blood flow and GFR, although the ejection fraction comparably increased with both drugs. 7 A randomized clinical trial of carvedilol and enalapril for 18 months in 572 patients with mild heart failure showed that enalapril slightly increased, whereas carvedilol reduced serum creatinine levels that had been normal at the start of the study. 8 Only a few studies have investigated the effects of carvedilol on renal function or clinical outcomes in patients with heart failure and renal dysfunction, excluding investigations of patients on hemodialysis. In this respect, the findings of Ito et al showing that eGFR significantly decreased in patients given metoprolol, but did not change in those given carvedilol, are relevant. Unfortunately, however, data about renal function during follow-up were not available for over half of the enrolled population in their study. A small study that examined the effects of switching from bisoprolol to carvedilol and vice versa on the renal function of 23 and 30 patients with chronic heart failure and moderate to severe renal dysfunction, respectively, found no change in the creatinine values of either group after 4 weeks. 9 In conclusion, β-blockers can be administered to patients with systolic heart failure and mild to severe renal dysfunction. Although carvedilol seems preferable because of its pharmacological profile, further clinical investigations are required to establish the optimal strategy for treating such patients.
